Author + information
- Received December 30, 1985
- Revision received August 20, 1986
- Accepted September 4, 1986
- Published online March 1, 1987.
- Steven Kurzrok, MD1,
- Arun K. Singh, MD, FACC1,
- Albert S. Most, MD, FACC1 and
- David O. Williams, MD, FACC*,1
- ↵*Address for reprints: David O. Williams, MD, Division of Cardiology, Rhode Island Hospital, 593 Eddy Street, Providence, Rhode Island 02902.
To determine the efficacy and safety of thrombolytic therapy for prosthetic valve thrombosis, a composite series of 41 patients who received either streptokinase or urokinase intravenously for this disorder were analyzed. The series comprised 3 patients treated at Rhode Island Hospital and 38 previously reported on. Short-term success was achieved in 32 patients (78%). Prosthetic valve thrombosis recurred in seven (22%) of the successfully treated patients, four of whom were retreated with thrombolytic therapy. A favorable clinical outcome was observed in each.
Fever and venipuncture bleeding were the most frequent side effects. Systemic embolization occurred in 4 (15%) of 26 patients with either aortic or mitral prosthetic valve thrombosis. None of these latter patients experienced a permanent neurologic or circulatory deficit. It is concluded that thrombolytic therapy is of value in the treatment of prosthetic valve thrombosis.
- Received December 30, 1985.
- Revision received August 20, 1986.
- Accepted September 4, 1986.
- American College of Cardiology Foundation